CRISPR Journal

Papers
(The TQCC of CRISPR Journal is 7. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)
ArticleCitations
Will Advances in Genetic Medicine Lessen the Need for Germline Modifications?508
Exploring the Cytoplasmic Retention of CRISPR-Cas9 in Eukaryotic Cells: The Role of Nuclear Localization Signals and Ribosomal Interactions52
Adaptation by Type V-A and V-B CRISPR-Cas Systems Demonstrates Conserved Protospacer Selection Mechanisms Between Diverse CRISPR-Cas Types51
Increasing Genome Editing Efficiency of Cas9 Nucleases by the Simultaneous Use of Transcriptional Activators and Histone Acetyltransferase Activator42
Hairpin Internal Nuclear Localization Signals in CRISPR-Cas9 Enhance Editing in Primary Human Lymphocytes41
Gene Editing Corrects In Vitro a G > A GLB1 Transition from a GM1 Gangliosidosis Patient40
CRISPR Comparison Toolkit: Rapid Identification, Visualization, and Analysis of CRISPR Array Diversity38
Inference of CRISPR Edits from Sanger Trace Data33
Gene Editing and Rett Syndrome: Does It Make the Cut?32
A Taxonomic and Phylogenetic Classification of Diverse Base Editors32
Opposing Human Genetic Engineering30
Curing “GFP-itis” in Bacteria with Base Editors: Development of a Genome Editing Science Program Implemented with High School Biology Students29
Advances in Cas12a-Based Amplification-Free Nucleic Acid Detection28
Acknowledgment of Reviewers 202228
Generation of a Commercial-Scale Founder Population of Porcine Reproductive and Respiratory Syndrome Virus Resistant Pigs Using CRISPR-Cas24
Novel CRISPR-Associated Gene-Editing Systems Discovered in Metagenomic Samples Enable Efficient and Specific Genome Engineering24
The Lexicon of CRISPR: When Is It Too Much?23
Early Detection of Wildlife Disease Pathogens Using CRISPR-Cas System Methods22
Efficient Installation of Heterozygous Mutations in Human Pluripotent Stem Cells Using Prime Editing22
Increasing the Targeting Scope of CRISPR Base Editing System Beyond NGG21
The Roles and Responsibilities of Scientific Journals in Research Governance: Editorial Policymaking at Nature and Springer Nature (1995–2023)18
CRISPR Crops and Sustainable Agriculture18
Implementing CRISPR-Cas9 Yeast Practicals into Biology Curricula18
Generation of Human Isogenic Induced Pluripotent Stem Cell Lines with CRISPR Prime Editing17
Comprehensive Analysis of CRISPR-Cas9 Editing Outcomes in Yeast Xanthophyllomyces dendrorhous17
Efficient Homology-Directed Repair with Circular Single-Stranded DNA Donors16
CRISPR Rewrites the Future of Medicine15
CRISPR à la carte15
A Story of Perseverance: An Interview with Matthew Porteus14
Specific High-Sensitivity Enzymatic Reporter UnLOCKing-Mediated Detection of Oncogenic BCR::ABL1 and EGFR Rearrangements13
dCas9 Tells Tales: Probing Gene Function and Transcription Regulation in Cancer13
CRISPR-Cas9 Single Nucleotide Editing of Tuberous Sclerosis Complex 2 Gene in Mesenchymal Stem Cells13
Engineering CjCas9 for Efficient Base Editing and Prime Editing13
Institutional Bioethics: From Critical Interdisciplinarity to Cosmopolitanism12
Automated Good Manufacturing Practice-Compatible CRISPR-Cas9 Editing of Hematopoietic Stem and Progenitor Cells for Clinical Treatment of β-Hemoglobinopathies12
Widespread Impact of Natural Genetic Variations in CRISPR-Cas9 Outcomes12
Evolutionary Biology and Gene Editing of Cat Allergen, Fel d 111
Combined Theoretical, Bioinformatic, and Biochemical Analyses of RNA Editing by Adenine Base Editors11
CRISPR Momentum in the Clinic and the Field11
Gene Editing in the Chagas Disease Vector Rhodnius prolixus by Cas9-Mediated ReMOT Control11
Engineered Antiviral Sensor Targets Infected Mosquitoes11
Rational Engineering of CRISPR-Cas9 Nuclease to Attenuate Position-Dependent Off-Target Effects11
Affordable Pricing of CRISPR Treatments is a Pressing Ethical Imperative10
A Multiplexed Cas13-Based Assay with Point-of-Care Attributes for Simultaneous COVID-19 Diagnosis and Variant Surveillance10
Efficient CRISPR-Cas9-Mediated Genome Editing of the Cane Toad (Rhinella marina)10
A Fluorescent Reporter Mouse for In Vivo Assessment of Genome Editing with Diverse Cas Nucleases and Prime Editors10
Enhancements of the CRISPR-Cas System in the Silkworm Bombyx mori10
A PCR-Induced Mutagenesis-Restriction Fragment Length Polymorphism Method for the Detection of CRISPR-Induced Indels10
Cas12a-Capture: A Novel, Low-Cost, and Scalable Method for Targeted Sequencing9
The CRISPR Revolution in the Drug Discovery Workflow: An Industry Perspective9
Fanzors: Mysterious TnpB-Like Bacterial Transposon-Related RNA-Guided DNA Nucleases of Eukaryotes9
Warrior Spirit: An Interview with Victoria Gray, Sickle Cell Pioneer9
A Protein-Cutting CRISPR Complex Caught in Action9
It's a Knockout for Cat Allergies?9
Introducing Faith-Based Claims to Ethical Discourse on Scientific Matters8
Bacterial Retrons Enable Precise Gene Editing in Human Cells8
Rapid and Technically Simple Detection of SARS-CoV-2 Variants Using CRISPR Cas12 and Cas138
Acknowledgment of Reviewers 20237
CRISPR-Cas9 Gene Editing Protects from the A53T-SNCA Overexpression-Induced Pathology of Parkinson's Disease In Vivo7
Moving Therapeutic Genome Editing into Global Clinical Trials and Medicine7
Reduction of Pre-Existing Adaptive Immune Responses Against SaCas9 in Humans Using Epitope Mapping and Identification7
CRISPR-Cas9-Mediated Correction of TSC2 Pathogenic Variants in iPSCs from Patients with Tuberous Sclerosis Complex Type 27
Genome Editing Therapy for the Blood: Ex Vivo Success and In Vivo Prospects7
Genome Editing Headwinds: Can CRISPR Stay on Target?7
Trichostatin A for Efficient CRISPR-Cas9 Gene Editing of Human Pluripotent Stem Cells7
Navigating Viral Space with CRISPR Technologies7
Rapid Variant Pathogenicity Analysis by CRISPR Activation of CRB1 Gene Expression in Patient-Derived Fibroblasts7
The New Old Colonialism7
Base Editing of Somatic Cells Using CRISPR–Cas9 in Drosophila7
Five Years of Progress in CRISPR Clinical Trials (2019–2024)7
0.094016075134277